Company

Sinocelltech

神州细胞

Sinocelltech (神州细胞, SSE STAR Market: 688520.SH) is a Beijing biotech and a Qiming Venture Partners portfolio company, repeatedly named by Qiming as one of the most influential firms in its healthcare portfolio . Its flagship product is finolimab (安佑平®, SCT-I10A), a self-developed recombinant humanized anti-PD-1 monoclonal antibody: in February 2025 it won NMPA approval for first-line head and neck squamous cell carcinoma and, combined with bevacizumab, for first-line unresectable or metastatic hepatocellular carcinoma — its second PD-1 indication, backed by a Phase 3 trial that beat sorafenib on response rate, progression-free and overall survival . By March 2025 the first commercial batches had shipped and initial prescriptions were written in Beijing and Hebei, marking the start of its commercial rollout . Beyond PD-1, its pipeline includes SCTB39-1, an in-house multi-target trispecific antibody cleared by the NMPA in mid-2025 for trials as monotherapy in advanced solid tumors . elsewhere's corpus is thin on the company's founding history and financials — what's here comes mainly from Qiming's portfolio updates.

AI-generated — may contain errors, please verify.

SinocelltechCompany
神州细胞
渲染中…
Mentioned in 131 articles

Coverage